PresentationDaniel Cohen Good afternoon. Thanks for joining us. I'm Daniel Cohen. I'm a Managing Director in the -- at Morgan Stanley. I do have to read a disclosure before we start. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, we will kick it off. Very honored to have my friend, Paul Josephs, CEO of Lifecore, here with ...

Lifecore Biomedical (NasdaqGS:LFCR) FY Conference September 09, 2025 04:50 PM ET Company ParticipantsDaniel Cohen - Managing DirectorPaul Josephs - CEODaniel CohenGood afternoon. Thanks for joining us. I'm Daniel Cohen. I'm a Managing Director at Morgan Stanley. I do have to read a disclosure before we start. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com. If you have any questions, please reach out to your Morgan Stanley sales representative. W ...

CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brunswick, NJ. Lifecor ...

CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceDetails: Lifecore management will participate in a fireside chat and in investor meetingsConference Dates: September 8- ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against LifeCore Biomedical, Inc. (NASDAQ: LFCR) on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Summary by Sections Legal Investigation - The investigation is focused on claims made in a class action complaint filed on July 29, 2024, concerning the period from October 7, 2020, to March 19, 2024 [1] - The law firm encourages long-term stockholders who suffered losses to contact them for discussions regarding their legal rights [1][3] Allegations Against LifeCore - The complaint alleges that LifeCore made materially false and misleading statements about its business, operations, and prospects during the class period [2] - Specific allegations include: - Deficient internal controls over financial reporting [2] - Issuance of inaccurate financial statements that would require restatement [2] - Ineffective remediation efforts regarding the identified deficiencies [2] - Impaired ability to file periodic reports with the SEC in compliance with NASDAQ requirements [2] - Material overstatement of the company's financial position and prospects [2] - Public statements being materially false and misleading throughout the relevant period [2] Contact Information - Long-term stockholders with information or questions are encouraged to reach out to the law firm via email or phone [3][6]

This presentation contains non-GAAP financial information including Adjusted EBITDA. The Company has included a reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable financial measure calculated in accordance with GAAP. We define Adjusted EBITDA as net (loss) income as determined under GAAP excluding (i) interest expense, net of interest income, (ii) income tax expense (benefit), (iii) depreciation and amortization, (iv) stock-based compensation, (v) change in fair value of de ...

This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this agricultural and food packaging products company would post a loss of $0.14 per share when it actually produced a loss of $0.19, delivering a surprise of -35.71%. Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. Ove ...

Lifecore Biomedical (LFCR) Q4 2025 Earnings Call August 07, 2025 04:30 PM ET Speaker0Thank you, Stephanie. Good afternoon, everyone, and thank you for joining our fiscal twenty twenty five fourth quarter and full year update. Fiscal twenty twenty five was a strong year for Lifecore Biomedical. As you may recall, I joined the company in May 2024 and immediately began to tackle a number of challenges. I am pleased to report that with a new strategic plan and proven CDMO leadership, we were highly successful i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 25, 2025, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other juris ...

Exhibit 99.1 Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update -- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid- Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- "Driven by our ...